Search research articles
Contact Us
Filters
Showing results (81-90 of 144) with videos related to
Page
of 15
Sort By:
Journal of Clinical Lipidology
|
December 29, 2018
Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial
Robert Dufour, G Kees Hovingh, John R Guyton, et al.
BMC Cardiovascular Disorders
|
September 22, 2014
Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials
Helen M Colhoun, Jennifer G Robinson, Michel Farnier, et al.
Journal of the American College of Cardiology
|
February 4, 2017
Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials
Jennifer G Robinson, Robert S Rosenson, Michel Farnier, et al.
Coronary Artery Disease
|
October 15, 2016
Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia
John J P Kastelein, Dean J Kereiakes, Christopher P Cannon, et al.
Journal of Clinical Lipidology
|
February 5, 2011
Comparison of short-term renal effects and efficacy of rosuvastatin 40 mg and simvastatin 80 mg, followed by assessment of long-term renal effects of rosuvastatin 40 mg, in patients with dyslipidemia
Evan A Stein, A David Marais, Jean Ducobu, et al.
Diabetes & Vascular Disease Research
|
August 24, 2011
Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome
Maurizio Averna, Luc Missault, Helena Vaverkova, et al.
European Journal of Preventive Cardiology
|
September 22, 2022
Projected impact of treatment intensification with statin, ezetimibe, and statin plus ezetimibe fixed-dose combination on MACE across six countries
Michel Farnier, Raul D Santos, Juan Cosin-Sales, et al.
Journal of Clinical Lipidology
|
September 29, 2016
The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients
Sophie Béliard, Aurélie Millier, Valérie Carreau, et al.
Lipids in Health and Disease
|
May 5, 2021
Coronary lesion complexity in patients with heterozygous familial hypercholesterolemia hospitalized for acute myocardial infarction: data from the RICO survey
Hermann Yao, Michel Farnier, Laura Tribouillard, et al.
Cardiovascular Drugs and Therapy
|
May 21, 2014
Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies
John J P Kastelein, Jennifer G Robinson, Michel Farnier, et al.
Page
of 15
Search research articles
Search
Showing results (81-90 of 144) with videos related to
Sort By:
Page
of 15
Journal of Clinical Lipidology
|
December 29, 2018
Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial
Robert Dufour, G Kees Hovingh, John R Guyton, et al.
BMC Cardiovascular Disorders
|
September 22, 2014
Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials
Helen M Colhoun, Jennifer G Robinson, Michel Farnier, et al.
Journal of the American College of Cardiology
|
February 4, 2017
Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials
Jennifer G Robinson, Robert S Rosenson, Michel Farnier, et al.
Coronary Artery Disease
|
October 15, 2016
Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia
John J P Kastelein, Dean J Kereiakes, Christopher P Cannon, et al.
Journal of Clinical Lipidology
|
February 5, 2011
Comparison of short-term renal effects and efficacy of rosuvastatin 40 mg and simvastatin 80 mg, followed by assessment of long-term renal effects of rosuvastatin 40 mg, in patients with dyslipidemia
Evan A Stein, A David Marais, Jean Ducobu, et al.
Diabetes & Vascular Disease Research
|
August 24, 2011
Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome
Maurizio Averna, Luc Missault, Helena Vaverkova, et al.
European Journal of Preventive Cardiology
|
September 22, 2022
Projected impact of treatment intensification with statin, ezetimibe, and statin plus ezetimibe fixed-dose combination on MACE across six countries
Michel Farnier, Raul D Santos, Juan Cosin-Sales, et al.
Journal of Clinical Lipidology
|
September 29, 2016
The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients
Sophie Béliard, Aurélie Millier, Valérie Carreau, et al.
Lipids in Health and Disease
|
May 5, 2021
Coronary lesion complexity in patients with heterozygous familial hypercholesterolemia hospitalized for acute myocardial infarction: data from the RICO survey
Hermann Yao, Michel Farnier, Laura Tribouillard, et al.
Cardiovascular Drugs and Therapy
|
May 21, 2014
Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies
John J P Kastelein, Jennifer G Robinson, Michel Farnier, et al.
Page
of 15